The global TNF Inhibitors market size was estimated at USD 4.2 billion in 2021 and is expected to surpass around USD 20.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.2 during the forecast period 2022 to 2030.
The rise in global occurrence of autoimmune illnesses such as Psoriasis, Inflammatory Bowel Disorder, Rheumatoid Arthritis (RA), and Crohn's disease, as well as the rise in the elderly populace, are the primary reasons likely to drive the expansion of the global TNF inhibitors market.
Golimumab, Etanercept, Certolizumab, Infliximab, and Adalimumab are TNF inhibitors utilized to address inflammatory illnesses such as inflammatory bowel disease and psoriasis. Manufacturers in the global TNF inhibitors market are likely to provide a wide range of medications to treat a variety of inflammatory illnesses. During the COVID-19 pandemic, however, a research found that if a patient was completely vaccinated with the Pfizer vaccine and was taking a TNF inhibitor, the patient's antibody response to the virus that caused COVID-19 was diminished. A third injection of the vaccine, according to the study, is likely to boost antibody levels in the body.
The global TNF inhibitors market is relatively competitive, with many prominent competitors. In terms of market share, a few major competitors currently dominate the industry. Some major players are purchasing other businesses in order to strengthen their global market positions, whilst others are developing new items. With the clearance of the US Food and Drug Administration (FDA) in December 2019, Amgen added another blockbuster medicine, AVSOLA (infliximab-axxq), to its current portfolio of biosimilar drugs. As of the reference product, Remicade (infliximab), the AVSOLA has been authorized for all indications of chronic inflammatory diseases, which is projected to boost the global TNF inhibitors market in the years to come.
Report Scope of the TNF Inhibitors Market
|
Report Coverage |
Details |
|
Market Size |
USD 20.4 Billion by 2030 |
|
Growth Rate |
CAGR of 11.2 % from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Drug, Application, Distribution Channel,And Region |
|
Companies Mentioned |
AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., UCB Inc., Samsung Bioepis, Biogen, Merck & Co., Takeda Pharmaceutical Company, Pfizer, Inc. |
Presence of Advanced Healthcare Facilities and Favorable Policies to Drive Demand in the Market
The world's population is aging rapidly, particularly in developed countries, such as the U.S., Japan, and Western Europe. In comparison to developing countries, developed countries have higher rate of aging. This can be linked to these nations' steadily growing health infrastructure, reimbursement systems, and advancements in health-care facilities. In addition to that, availability to numerous TNF inhibitors has increased, particularly in developed nations. As a result, the people's life expectancy has grown. The senior population is a big fan of TNF inhibitors since they help them live longer and better lives. An increase in the number of aged individuals leads to a higher risk of illness, which is anticipated to drive up demand in the global TNF inhibitors in the years to come.
High Prevalence of Rheumatoid Arthritis to Spell Growth for the Market
The US Food and Drug Administration authorized adalimumab, often known as Humira, as the first and only entirely human monoclonal antibody for the treatment of rheumatoid arthritis. Humira, AbbVie's largest medication, was released in 2003 and has consistently generated the most revenue for the firm, which is likely to fuel expansion of the global TNF inhibitors market in the years to come.
Due to its widespread prevalence, rheumatoid arthritis is likely to account for substantial chunk of the global TNF inhibitors market. Furthermore, rheumatoid arthritis is more common in women than in men, is predicted to account for around two-thirds of the entire patient population with arthritis, and it worsens with age, all of which are expected to move the global TNF inhibitors market forward.
Hospital pharmacies are predicted to acquire one of the leading market shares by owing to the availability of physicians and treatment in one single location. Additionally, biosimilars producers want to control the availability of their goods to as many hospitals and patients as possible in order to fulfill their increasing requirements, which is expected to fuel the segment's growth and contribute to its part of global market revenue.
Growing Prevalence of TNF Inhibitor Biosimilars is Expected to Support Market Expansion
Most of the major TNF inhibitors, such as remicade, Enbrel, and humira, have lost their patents in the recent years, and more TNF inhibitors are anticipated to lose their patents soon. As a result of patient affordability in low-income countries and increasing patient awareness, TNF inhibitor biosimilars are expected to acquire market share throughout the projection period. In 2022, the patent on humira (adalimumab), the world's most popular medication, expired. In 2014, Johnson & Johnson's remicade lost its patent. TNF inhibitor biosimilars are projected to open up profitable potential in low-income nations by making TNF inhibitors more accessible and inexpensive, which will likely increase TNF inhibitor usage. This, in turn, is expected to fuel the demand for TNF inhibitors. Furthermore, a robust clinical pipeline of TNF inhibitors biosimilars is anticipated to bolster growth of the global TNF inhibitors market.
North America and Europe to Lead the Market due to the Presence of Huge Ageing Population Base
North America is likely to lead the global TNF inhibitors market during the forecast period. The region's prominence is attributed to a number of factors, including well-established direct reimbursement regulations and the presence of superior healthcare infrastructure. Due to the USFDA's fast medication approval effort, which supported market expansion in this region, the US is likely to account for a substantial chunk of the market in the years to come.
Following North America, Europe is likely to account for the second-largest market for TNF inhibitors, driven by growing demand from the regional aging population and rising healthcare costs. Huge expenditures by leading players, as well as continued expansion in R&D efforts in the area, are likely to contribute significantly to market revenue during the forecast period.
Asia Pacific is expected to expand at a rapid growth rate, owing to the large patient populations in China and India for disorders including Crohn's disease, IBD, and psoriasis. Furthermore, an expansion in the role of the government in assisting the healthcare industry, as well as continuous research activities in the region, is likely to boost market growth in the region.
Some of the prominent players in the TNF Inhibitors Market include:
AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., UCB Inc., Samsung Bioepis, Biogen, Merck & Co., Takeda Pharmaceutical Company, Pfizer, Inc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global TNF Inhibitors market
By Drug
By Application
Distribution Channel
By Regional Outlook
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global TNF Inhibitors Market: Market Snapshot
4. Market Overview
4.1. Global TNF Inhibitors Market: Overview
4.2. Global TNF Inhibitors Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Trends
4.4. Global TNF Inhibitors Market Size (US$ Mn) Forecast, 2022–2030
4.5. Global TNF Inhibitors Market Outlook
4.6. Porter’s Five Forces Analysis
4.7. Clinical trials pipeline analysis-TNF Inhibitors
4.8. Overview of Regulatory Framework for Development and Approval of Biosimilars
5. Global TNF Inhibitors Market Analysis, by Drug
5.1. Key Findings
5.2. Introduction
5.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Drug
5.4. Global TNF Inhibitors Market Value Forecast, by Drug
5.4.1. Adalimumab
5.4.2. Certolizumab
5.4.3. Etanercept
5.4.4. Golimumab
5.4.5. Infliximab
5.5. Global TNF Inhibitors Market Analysis, by Drug
6. Global TNF Inhibitors Market Analysis, by Application
6.1. Key Findings
6.2. Introduction
6.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Application
6.4. Global TNF Inhibitors Market Value Forecast, by Application
6.4.1. Rheumatoid Arthritis
6.4.2. Psoriasis
6.4.3. Inflammatory Bowel Disease
6.4.4. Ankylosing Spondylitis
6.4.5. Others
6.5. Global TNF Inhibitors Market Analysis, by Application
7. Global TNF Inhibitors Market Analysis, by Distribution channel
7.1. Key Findings
7.2. Introduction
7.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Distribution Channel
7.4. Global TNF Inhibitors Market Value Forecast, by Distribution channel
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Global TNF Inhibitors Market Analysis, by Distribution Channel
8. Global TNF Inhibitors Market Analysis, by Region
8.1. Global TNF Inhibitors Market Scenario, by Country
8.2. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Region
8.3. Global TNF Inhibitors Market Value Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America TNF Inhibitors Market Analysis and Forecast
9.1. Key Findings
9.2. North America TNF Inhibitors Market Overview
9.3. North America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
9.4. North America TNF Inhibitors Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America TNF Inhibitors Market Value Share Analysis, by Drug
9.6. North America TNF Inhibitors Market Forecast, by Drug
9.6.1. Adalimumab
9.6.2. Certolizumab
9.6.3. Etanercept
9.6.4. Golimumab
9.6.5. Infliximab
9.7. North America TNF Inhibitors Market Value Share Analysis, by Application
9.8. North America TNF Inhibitors Market Forecast, by Application
9.8.1. Rheumatoid Arthritis
9.8.2. Psoriasis
9.8.3. Inflammatory Bowel Disease
9.8.4. Ankylosing Spondylitis
9.8.5. Others
9.9. North America TNF Inhibitors Market Value Share Analysis, by Distribution channel
9.10. North America TNF Inhibitors Market Forecast, by Distribution channel
9.10.1. Hospital Pharmacy
9.10.2. Retail Pharmacy
9.10.3. Online Pharmacy
9.11. North America TNF Inhibitors Market Attractiveness Analysis
10. Europe TNF Inhibitors Market Analysis
10.1. Key Findings
10.2. Europe TNF Inhibitors Market Overview
10.3. Europe TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
10.4. Europe TNF Inhibitors Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe TNF Inhibitors Market Value Share Analysis, by Drug
10.6. Europe TNF Inhibitors Market Forecast, by Drug
10.6.1. Adalimumab
10.6.2. Certolizumab
10.6.3. Etanercept
10.6.4. Golimumab
10.6.5. Infliximab
10.7. Europe TNF Inhibitors Market Value Share Analysis, by Application
10.8. Europe TNF Inhibitors Market Forecast, by Application
10.8.1. Rheumatoid Arthritis
10.8.2. Psoriasis
10.8.3. Inflammatory Bowel Disease
10.8.4. Ankylosing Spondylitis
10.8.5. Others
10.9. Europe TNF Inhibitors Market Value Share Analysis, by Distribution channel
10.10. Europe TNF Inhibitors Market Forecast, by Distribution channel
10.10.1. Hospital Pharmacy
10.10.2. Retail Pharmacy
10.10.3. Online Pharmacy
10.11. Europe TNF Inhibitors Market Attractiveness Analysis
11. Asia Pacific TNF Inhibitors Market Analysis
11.1. Key Findings
11.2. Asia Pacific TNF Inhibitors Market Overview
11.3. Asia Pacific TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
11.4. Asia Pacific TNF Inhibitors Market Forecast, by Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Drug
11.6. Asia Pacific TNF Inhibitors Market Forecast, by Drug
11.6.1. Adalimumab
11.6.2. Certolizumab
11.6.3. Etanercept
11.6.4. Golimumab
11.6.5. Infliximab
11.7. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Application
11.8. Asia Pacific TNF Inhibitors Market Forecast, by Application
11.8.1. Rheumatoid Arthritis
11.8.2. Psoriasis
11.8.3. Inflammatory Bowel Disease
11.8.4. Ankylosing Spondylitis
11.8.5. Others
11.9. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Distribution channel
11.10. Asia Pacific TNF Inhibitors Market Forecast, by Distribution channel
11.10.1. Hospital Pharmacy
11.10.2. Retail Pharmacy
11.10.3. Online Pharmacy
11.11. Asia Pacific TNF Inhibitors Market Attractiveness Analysis
12. Latin America TNF Inhibitors Market Analysis
12.1. Key Findings
12.2. Latin America TNF Inhibitors Market Overview
12.3. Latin America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
12.4. Latin America TNF Inhibitors Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America TNF Inhibitors Market Value Share Analysis, by Drug
12.6. Latin America TNF Inhibitors Market Forecast, by Drug
12.6.1. Adalimumab
12.6.2. Certolizumab
12.6.3. Etanercept
12.6.4. Golimumab
12.6.5. Infliximab
12.7. Latin America TNF Inhibitors Market Value Share Analysis, by Application
12.8. Latin America TNF Inhibitors Market Forecast, by Application
12.8.1. Rheumatoid Arthritis
12.8.2. Psoriasis
12.8.3. Inflammatory Bowel Disease
12.8.4. Ankylosing Spondylitis
12.8.5. Others
12.9. Latin America TNF Inhibitors Market Value Share Analysis, by Distribution channel
12.10. Latin America TNF Inhibitors Market Forecast, by Distribution channel
12.10.1. Hospital Pharmacy
12.10.2. Retail Pharmacy
12.10.3. Online Pharmacy
12.11. Latin America TNF Inhibitors Market Attractiveness Analysis
13. Middle East & Africa TNF Inhibitors Market Analysis
13.1. Key Findings
13.2. Middle East & Africa TNF Inhibitors Market Overview
13.3. Middle East & Africa TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
13.4. Middle East & Africa TNF Inhibitors Market Forecast, by Country
13.4.1. South Africa
13.4.2. UAE
13.4.3. Saudi Arabia
13.4.4. Rest of Middle East and Africa
13.5. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Drug
13.6. Middle East & Africa TNF Inhibitors Market Forecast, by Drug
13.6.1. Adalimumab
13.6.2. Certolizumab
13.6.3. Etanercept
13.6.4. Golimumab
13.6.5. Infliximab
13.7. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Application
13.8. Middle East & Africa TNF Inhibitors Market Forecast, by Application
13.8.1. Rheumatoid Arthritis
13.8.2. Psoriasis
13.8.3. Inflammatory Bowel Disease
13.8.4. Ankylosing Spondylitis
13.8.5. Others
13.9. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Distribution channel
13.10. Middle East & Africa TNF Inhibitors Market Forecast, by Distribution channel
13.10.1. Hospital Pharmacy
13.10.2. Retail Pharmacy
13.10.3. Online Pharmacy
13.11. Middle East & Africa TNF Inhibitors Market Attractiveness Analysis
14. Competitive Landscape
14.1. Company Profiles
14.1.1. AbbVie, Inc.
14.1.1.1.1. Company Details
14.1.1.1.2. Business Overview
14.1.1.1.3. Financial Overview
14.1.1.1.4. Strategic Overview
14.1.1.1.5. SWOT Analysis
14.1.2. Janssen Biotech, Inc.
14.1.2.1.1. Company Details
14.1.2.1.2. Business Overview
14.1.2.1.3. Financial Overview
14.1.2.1.4. Strategic Overview
14.1.2.1.5. SWOT Analysis
14.1.3. Amgen, Inc.
14.1.3.1.1. Company Details
14.1.3.1.2. Business Overview
14.1.3.1.3. Financial Overview
14.1.3.1.4. Strategic Overview
14.1.3.1.5. SWOT Analysis
14.1.4. UCB Inc.
14.1.4.1.1. Company Details
14.1.4.1.2. Business Overview
14.1.4.1.3. Financial Overview
14.1.4.1.4. Strategic Overview
14.1.4.1.5. SWOT Analysis
14.1.5. Samsung Bioepis
14.1.5.1.1. Company Details
14.1.5.1.2. Business Overview
14.1.5.1.3. Financial Overview
14.1.5.1.4. Strategic Overview
14.1.5.1.5. SWOT Analysis
14.1.6. Biogen
14.1.6.1.1. Company Details
14.1.6.1.2. Business Overview
14.1.6.1.3. Financial Overview
14.1.6.1.4. Strategic Overview
14.1.6.1.5. SWOT Analysis
14.1.7. Merck & Co.
14.1.7.1.1. Company Details
14.1.7.1.2. Business Overview
14.1.7.1.3. Financial Overview
14.1.7.1.4. Strategic Overview
14.1.7.1.5. SWOT Analysis
14.1.8. Takeda Pharmaceutical Company
14.1.8.1.1. Company Details
14.1.8.1.2. Business Overview
14.1.8.1.3. Financial Overview
14.1.8.1.4. Strategic Overview
14.1.8.1.5. SWOT Analysis
14.1.9. Pfizer, Inc.
14.1.9.1.1. Company Details
14.1.9.1.2. Business Overview
14.1.9.1.3. Financial Overview
14.1.9.1.4. Strategic Overview
14.1.9.1.5. SWOT Analysis
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers